» Articles » PMID: 39091902

Fast and Simple Voltammetric Sensing of Avanafil in the Pharmaceutical Formulation by Using Unmodified Boron-doped Diamond Electrode

Overview
Journal ADMET DMPK
Specialty Pharmacology
Date 2024 Aug 2
PMID 39091902
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Erectile dysfunction is a common issue among adult males involving difficulty in maintaining an erection, and it is often treated with fast-acting, low-side-effect drugs like avanafil (AVN), among other phosphodiesterase-5 inhibitors. Hence, developing fast, simple, and sensitive methods to detect AVN is crucial.

Experimental Approach: This study conducts an electroanalytical inquiry and provides a new voltammetric method for accurately analyzing AVN utilizing a boron-doped diamond (BDD) electrode without any modifications.

Key Results: In the Britton-Robinson buffer (BR, 0.04 mol L, pH 4.0), cyclic voltammetry showed a clearly defined and irreversible anodic peak at around +1.44 V relative to Ag/AgCl. The pH of the solution was shown to have an impact on the voltammetric signals of the oxidation peaks. A good linear response for AVN quantification was achieved using square-wave voltammetry. This was done in a 0.04 mol L-1 BR (pH 4.0) solution at a potential of +1.33 V ( Ag/AgCl). The method exhibited a wide dynamic range of 0.5 to 30.0 μg mL (1.0 to 62 μmol L) and a low limit of detection of 0.14 μg mL (0.29 μmol L). The method proposed demonstrated suitability for determining AVN content in pharmaceutical formulations. The accuracy of the approach was demonstrated by comparing the results obtained using the developed method with those achieved using the UV-Vis spectrometry method.

Conclusion: Our method simplifies the analytical process by eliminating the need for electrode modification, reducing both time and resource requirements while enhancing overall feasibility.

References
1.
Al Ashmawy A, Alyami M, Eissa N, Balata G, El Nahas H . Oral bioavailability enhancement of doxazosin mesylate: Nanosuspension versus self-nanoemulsifying drug delivery systems. ADMET DMPK. 2024; 12(1):167-176. PMC: 10974821. DOI: 10.5599/admet.2022. View

2.
Jung J, Choi S, Cho S, Ghim J, Hwang A, Kim U . Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther. 2010; 32(6):1178-87. DOI: 10.1016/j.clinthera.2010.06.011. View

3.
Kammoun A, Khedr A, Ahmed O . LC-MS/MS determination of avanafil and its metabolites in rat plasma and brain: pharmacokinetic study after oral administration and transdermal film application. RSC Adv. 2022; 10(16):9407-9413. PMC: 9050051. DOI: 10.1039/d0ra00569j. View

4.
Corona G, Rastrelli G, Burri A, Jannini E, Maggi M . The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf. 2015; 15(2):237-47. DOI: 10.1517/14740338.2016.1130126. View

5.
Burke R, Evans J . Avanafil for treatment of erectile dysfunction: review of its potential. Vasc Health Risk Manag. 2012; 8:517-23. PMC: 3433322. DOI: 10.2147/VHRM.S26712. View